Jinlan 98+ EP/BP/USP Orforglipron
27 Inquiries
2212020-52-3
medical grade
98%
Shanghai/Ningbo/Qingdao
Jinlan
25kg/Cardboard Drum
2026-04-01
Peptides,API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOrforglipron (LY3502970) (GLP-1 receptor agonist 1) is GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.Basic Info-
Product Name:
Orforglipron
Other Name:1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron(LY3502970);LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833
CAS No.:2212020-52-3
Molecular Formula:C48H48F2N10O5
InChIKeys:USUWIEBBBWHKNI-BBGRWQLENA-N
Molecular Weight:882.97
EC Number:278-636-5
Color/Form:Off-white to light yellow
Categories:
Characteristics-
Density:
1.50±0.1 g/cm3(Predicted)
PKA:7.33±0.20(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptides,API,Intermediate
-
Location:
Room 606, Building 1, Fu Yi Commercial Center, Shangcheng District, Hangzhou City, Zhejiang Province - 1
-
Payment Terms:
100% TT in advance
-
Average lead Time:
275 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
51-100
-
Year of Establishment:
2020
-
-
Inquiry History27 Inquiries
Country Product Purchase Quantity Date Posted
Bulgaria
orforglipron
1 KG Aug 27, 2025
Austria
Orforglipron
1000 MT Jun 12, 2026
Switzerland
Orforglipron
10 MG Apr 25, 2026
United States
Orforglipron
20 G Apr 3, 2026
United States
Orforglipron
10 G Mar 29, 2026
United States
oforglipron
3 KG Jul 4, 2025
United Kingdom
Orforglipron
1 G Jul 9, 2026
Belgium
Orforglipron
1 G Jun 14, 2026
Puerto Rico
Orforglipron
1 G Mar 2, 2026
United States
Orforglipron
10 G Oct 24, 2025
United States
Orforglipron
1 G Sep 30, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
orforglipron
1 MT Sep 20, 2025
United States
Orforglipron
1 KG Apr 18, 2025
Canada
LY-3502970
10 G Feb 26, 2026
India
orforglipron
1.00 G Jul 16, 2026
United States
orforglipron
10 G Apr 20, 2026
United States
Orforglipron
10 G Apr 6, 2026
United States
orforglipron
1 G Mar 24, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Jinlan 98+ EP/BP/USP Osimertinib mesylate
medical grade / 98%
-
-
-
-
Jinlan 98+ EP/BP/USP Ripretinib
medical grade / 98%
-
-
-
-
Jinlan 98+ EP/BP/USP Everolimus
medical grade / 98%
-
-
-
-
Jinlan 98+ Veterinary Use Fluralaner EP/BP/USP
medical grade / 98%
-
-
-
-
Axitinib
medical grade / 98%
-
-
-
-
Jinlan 98+ EP/BP/USP Enlicitide Decanoate (MK0616)
medical grade / 98%
-